Project Grant R01AR084451
- This federal Project Grant award of $664,933 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis. The research will utilize a novel animal model to define the early pathogenic pathways driven by IL-17A that contribute to joint and skin inflammation,...
- This federal Project Grant award of $1,617,503 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting research to improve understanding and treatment of pain associated with psoriatic arthritis. The key products or services to be delivered through this award include: Improving and validating a mouse model for studying pain mechanisms in psoriatic arthritis....
- This federal Project Grant award of $390,913 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a mechanistic investigation into the role of the protein SERPINB3 in the pathogenesis of psoriasis. The research project, being conducted by Arizona State University, will explore the hypothesis that the misprocessing of SERPINB3 is the initiating factor in the...
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define and treat genetic abnormalities in overlapping rashes of psoriasis and atopic dermatitis (termed "PSO-AD"). The $628,968 award to the University of California, San Francisco will leverage innovative biomarker techniques, including spatial transcriptomics and...
- This $300,000 Project Grant award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to the University of Rochester. The project aims to "Decipher the Endotypes and Signature of Non-Response in a Humanized Murine Model of PSA" for psoriatic arthritis, a chronic inflammatory disease. The research will (1) identify cellular and molecular signatures across psoriatic arthritis tissue domains, (2) define CD8+ T cell...
- This Project Grant award, totaling $176,148.00 and effective from April 1, 2025 to March 31, 2030, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The funding supports a research project led by Dr. Maxime Kinet at the University of California, San Francisco (UCSF) that aims to elucidate the mechanisms by which PI16-expressing fibroblasts, a...
- The federal Project Grant award titled "Immune Cell Contributions to Inflammatory Arthritis" is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $735,460 award to Vanderbilt University Medical Center will support research to investigate the roles of B cells and inflammatory cytokines in the pathogenesis of psoriatic arthritis (PSA) using a mouse model...
- This federal Project Grant award, valued at $1,826,181.00 and effective from September 1, 2025 to August 31, 2028, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research grant program (CFDA 93.846). The grant aims to comprehensively understand the contribution of Langerhans cells, resident cells in the epidermis, to chronic itch associated with various skin and systemic diseases. The research...
- This federal Project Grant award of $129,035 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports a 5-year research training program. The award aims to advance the principal investigator's expertise in centrosome, cytoskeletal, and keratinocyte biology, with a focus on understanding the role of the centrosomal protein CEP43 in maintaining epidermal integrity and its...
- This $169,560.00 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research focused on understanding the role of the endogenous opioid system in regulating inflammation, itch, and pain associated with inflammatory skin diseases. The primary recipient, The Regents of the University of California, San Francisco (UCSF), will conduct this research...
This federal Project Grant award, valued at $1,901,310.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project aims to investigate how skin inflammation drives the development of psoriatic arthritis, a condition that affects up to one-third of individuals with psoriasis. The project will use a novel mouse model to study the role of epidermal immune signaling in triggering psoriatic joint inflammation, with the goal of identifying early biomarkers and potential therapeutic targets for this condition. The research is being conducted by the University of California, San Francisco, a prominent academic medical center and federal grant recipient known for its expertise in biomedical research and clinical services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.9m | 9/15/25 |